| 1. |
- Cserni, Gabor, et al.
(författare)
-
Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions
- 2011
-
Ingår i: European Journal of Cancer. - : Elsevier BV. - 1879-0852 .- 0959-8049. ; 47:6, s. 887-894
-
Tidskriftsartikel (refereegranskat)abstract
- Isolated tumour cells and micrometastases represent two different staging categories and are often dealt with differently when identified in sentinel lymph nodes of breast cancer patients. The reproducibility of these categories was found to be suboptimal in several studies. The new edition of the TNM (Tumour Node Metastasis) is expected to improve the reproducibility of these categories. Fifty cases of possible low-volume nodal involvement were represented by one to four digital images and were analysed by members of the European Working Group for Breast Screening Pathology (EWGBSP). The kappa value for interobserver agreement of the pN (TNM) staging categories and of the isolated tumour cells category were 0.55 and 0.56 reflecting moderate reproducibility, and the kappa of the micrometastatic category (0.62) reflected substantial reproducibility. This is an improvement over the results gained on the basis of the previous edition of the TNM. Maximal adherence to the category definitions supplemented by explanatory texts in the staging manual should result in more homogeneous nodal staging of breast cancer. (C) 2010 Elsevier Ltd. All rights reserved.
|
|
| 2. |
- Cserni, Gábor, et al.
(författare)
-
Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.
- 2014
-
Ingår i: Breast. - : Elsevier BV. - 1532-3080. ; 23:3, s. 259-263
-
Tidskriftsartikel (refereegranskat)abstract
- The Ki67 labelling index (LI - proportion of staining cells) is widely used to reflect proliferation in breast carcinomas. Several cut-off values have been suggested to distinguish between tumours with low and high proliferative activity. The aim of the current study was to evaluate the distribution of Ki67 LIs in breast carcinomas diagnosed at different institutions by different pathologists using the method reflecting their daily practice. Pathologists using Ki67 were asked to provide data (including the LI, type of the specimen, receptor status, grade) on 100 consecutively stained cases, as well as details of their evaluation. A full dataset of 1709 carcinomas was collected from 19 departments. The median Ki67 LI was 17% for all tumours and 14% for oestrogen receptor-positive and HER2-negative carcinomas. Tumours with higher mitotic counts were associated with higher Ki67 LIs. Ki67 LIs tended to cluster around values ending with 5 or 0 both in cases where the values were obtained by counting the proportion of stained tumour cell nuclei and those where the values were obtained by estimation. On the basis of the distribution pattern described, some currently used Ki67 LI cut off values are not realistic, and it is proposed to select more realistic values ending with 0 or 5.
|
|
| 3. |
- Grasso, Silvia, et al.
(författare)
-
The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries
- 2017
-
Ingår i: Nature Communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 8
-
Tidskriftsartikel (refereegranskat)abstract
- The docking protein p140Cap negatively regulates tumour cell features. Its relevance on breast cancer patient survival, as well as its ability to counteract relevant cancer signalling pathways, are not fully understood. Here we report that in patients with ERBB2-amplified breast cancer, a p140Cap-positive status associates with a significantly lower probability of developing a distant event, and a clear difference in survival. p140Cap dampens ERBB2-positive tumour cell progression, impairing tumour onset and growth in the NeuT mouse model, and counteracting epithelial mesenchymal transition, resulting in decreased metastasis formation. One major mechanism is the ability of p140Cap to interfere with ERBB2-dependent activation of Rac GTPase-controlled circuitries. Our findings point to a specific role of p140Cap in curbing the aggressiveness of ERBB2-amplified breast cancers and suggest that, due to its ability to impinge on specific molecular pathways, p140Cap may represent a predictive biomarker of response to targeted anti-ERBB2 therapies.
|
|
| 4. |
- Malara, Natalia, et al.
(författare)
-
Multicancer screening test based on the detection of circulating non haematological proliferating atypical cells
- 2024
-
Ingår i: Molecular Cancer. - : BMC. - 1476-4598. ; 23:1
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Background the problem in early diagnosis of sporadic cancer is understanding the individual's risk to develop disease. In response to this need, global scientific research is focusing on developing predictive models based on non-invasive screening tests. A tentative solution to the problem may be a cancer screening blood-based test able to discover those cell requirements triggering subclinical and clinical onset latency, at the stage when the cell disorder, i.e. atypical epithelial hyperplasia, is still in a subclinical stage of proliferative dysregulation. Methods a well-established procedure to identify proliferating circulating tumor cells was deployed to measure the cell proliferation of circulating non-haematological cells which may suggest tumor pathology. Moreover, the data collected were processed by a supervised machine learning model to make the prediction. Results the developed test combining circulating non-haematological cell proliferation data and artificial intelligence shows 98.8% of accuracy, 100% sensitivity, and 95% specificity. Conclusion this proof of concept study demonstrates that integration of innovative non invasive methods and predictive-models can be decisive in assessing the health status of an individual, and achieve cutting-edge results in cancer prevention and management.
|
|
| 5. |
- Pekar, Gyula, 1973-
(författare)
-
Breast cancer : Multifocality, heterogeneity, and related genetic signatures
- 2016
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Breast carcinoma often exhibits a complex subgross morphology and may occupy a large volume of the breast tissue and show unifocal, multifocal or diffuse growth patterns. Expression of estrogen- and progesterone receptors, HER2 overexpression, tumor grade, and proliferative activity allows us to classify breast carcinoma into molecular subgroups (Luminal A, Luminal B, HER2-type, triple negative, and basal-like).We studied the relation of the spatial distribution of the lesions and their molecular phenotype in a consecutive series of 444 invasive breast carcinomas documented in large-format histology slides (paper I). The cumulative survival of patients diagnosed with unifocal cancer was significantly better than those who had multifocal or diffuse tumors in the luminal A, HER2-positive, and basal-like subgroups.We also studied the influence of intertumoral heterogeneity on survival in110 multifocal breast carcinomas (paper II). Patients with phenotypically heterogeneous multifocal cancers had a greater risk of dying from the disease (HR=2.879; 95%CI=1.08–7.65; P=0.034) and significantly shorter survival compared to non-heterogeneous cancers.The methodological issues regarding tissue sampling in multifocal breast carcinomas were addressed in paper III. A single 2 mm core from tumors contained sufficient DNA (> 2 µg) in most samples. Three cores using a 4-mm device were needed to obtain sufficient DNA from normal breast tissue.In paper IV, we focused on copy number aberrations in cancer-free breast tissue in a series of 282 breast cancer patients. Genome-wide Illumina SNP analysis was performed on fresh frozen samples and the results were morphologically confirmed in tissue samples adjacent to the fresh sample holes from large-section blocks using ERBB2/HER2 gene–protein assay. We observed genetic aberrations in normal breast tissue from 38.3% of patients. Gain of ERBB2 gene was the most common but additional growth factor receptor genes (EGFR, FGFR1, IGF1R, LIFR and NGFR) also showed recurrent gains.In conclusion, multifocality and phenotypical heterogeneity has an impact on patient survival. Post-zygotic structural genetic aberrations can often be observed in cancer-free breast tissue. Low copy number gain of ERBB2 is the most common aberration in normal breast cells and represents a cancer-predisposing mutation.
|
|
| 6. |
- Villegas, Victoria E, et al.
(författare)
-
Identification of novel non-coding RNA-based negative feedback regulating the expression of the oncogenic transcription factor GLI1.
- 2014
-
Ingår i: Molecular Oncology. - : Wiley. - 1574-7891 .- 1878-0261. ; 8:5, s. 912-26
-
Tidskriftsartikel (refereegranskat)abstract
- Non-coding RNAs are a complex class of nucleic acids, with growing evidence supporting regulatory roles in gene expression. Here we identify a non-coding RNA located head-to-head with the gene encoding the Glioma-associated oncogene 1 (GLI1), a transcriptional effector of multiple cancer-associated signaling pathways. The expression of this three-exon GLI1 antisense (GLI1AS) RNA in cancer cells was concordant with GLI1 levels. siRNAs knockdown of GLI1AS up-regulated GLI1 and increased cellular proliferation and tumor growth in a xenograft model system. Conversely, GLI1AS overexpression decreased the levels of GLI1, its target genes PTCH1 and PTCH2, and cellular proliferation. Additionally, we demonstrate that GLI1 knockdown reduced GLI1AS, while GLI1 overexpression increased GLI1AS, supporting the role of GLI1AS as a target gene of the GLI1 transcription factor. Activation of TGFβ and Hedgehog signaling, two known regulators of GLI1 expression, conferred a concordant up-regulation of GLI1 and GLI1AS in cancer cells. Finally, analysis of the mechanism underlying the interplay between GLI1 and GLI1AS indicates that the non-coding RNA elicits a local alteration of chromatin structure by increasing the silencing mark H3K27me3 and decreasing the recruitment of RNA polymerase II to this locus. Taken together, the data demonstrate the existence of a novel non-coding RNA-based negative feedback loop controlling GLI1 levels, thus expanding the repertoire of mechanisms regulating the expression of this oncogenic transcription factor.
|
|
| 7. |
- Wu, Chenglin, et al.
(författare)
-
RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples
- 2018
-
Ingår i: Communications biology. - : Springer Science and Business Media LLC. - 2399-3642. ; 1
-
Tidskriftsartikel (refereegranskat)abstract
- Single-molecule RNA fluorescence in situ hybridization (smFISH) represents a promising approach to quantify the expression of clinically useful biomarkers in tumor samples. However, routine application of smFISH to formalin-fixed, paraffin-embedded (FFPE) samples is challenging due to the low signal intensity and high background noise. Here we present RollFISH, a method combining the specificity of smFISH with the signal boosting of rolling circle amplification. We apply RollFISH to quantify widely used breast cancer biomarkers in cell lines and FFPE samples. Thanks to the high signal-to-noise ratio, we can visualize selected biomarkers at low magnification (20 x) across entire tissue sections, and thus assess their spatial heterogeneity. Lastly, we apply RollFISH to quantify HER2 mRNA in 150 samples on a single tissue microarray, achieving a sensitivity and specificity of detection of HER2-positive samples of similar to 90%. RollFISH is a robust method for quantifying the expression and intratumor heterogeneity of biomarkers in FFPE tissues.
|
|
